Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. - Wikidata - wikimedia - TriplyDB

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

http://www.wikidata.org/entity/Q46555308

about

Translatability scoring in drug development: eight case studies Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Alzheimer's therapeutics: translation of preclinical science to clinical drug development Targeting γ-secretase in breast cancer Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death.Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.Inhibitors of signal peptide peptidase (SPP) affect HSV-1 infectivity in vitro and in vivo.Targeting Abeta and tau in Alzheimer's disease, an early interim report Progress in Alzheimer's disease.Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Current and future treatments for Alzheimer's disease Disease-modifying treatments for Alzheimer's disease.Inhibitors of γ-secretase stabilize the complex and differentially affect processing of amyloid precursor protein and other substrates.Few-layer bismuth selenides exfoliated by hemin inhibit amyloid-β1-42 fibril formation.Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production.An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.Impact of amyloid imaging on drug development in Alzheimer's disease.Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.Emerging therapeutics for Alzheimer's disease.Disease modifying therapy for AD?In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects Current experimental therapy for Alzheimer's disease A novel high throughput 1536-well Notch1 γ -secretase AlphaLISA assay Present and prospective clinical therapeutic regimens for Alzheimer's disease.Looking for novel ways to treat the hallmarks of Alzheimer's disease.Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Inflammaging as a prodrome to Alzheimer's disease Gamma secretase inhibitors of Notch signaling Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.Gamma-secretase inhibition and modulation for Alzheimer's disease.Early diagnosis and treatment of Alzheimer's disease.Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

P2860

Q22241760-86CD37FD-6C36-4D7E-B7C5-CBFD0F77D4E4 Q24622136-56C4AD16-CF97-4B63-AB13-999F8562E441 Q26829267-1D7AFD63-4540-4B81-B024-F6D44283CE06 Q27001056-380A2D37-4C43-45D1-8BC1-7071CEF910B4 Q28072061-9C279061-4643-48BB-96F1-0A3C2D1CF4A7 Q30566020-24F100B3-F707-4B6E-8F08-866DD932BDA8 Q30584453-7AEEE9D4-9E53-4FCD-B4E5-03D8FF24EA70 Q31047131-7C3B33B4-E3AB-4AED-B333-6C20BCB0FEEC Q33289262-66B7FC09-E63F-4754-B947-0829BA87A8FE Q33391513-B9CA6C45-A426-49C4-BB0D-818EF3DAEBA1 Q33425212-D01ADF42-B005-43BB-97DD-C29252116155 Q33717645-88363660-D161-4D89-B2B7-BC2B253C9099 Q33829008-2CE93F5D-7E4B-4ABA-A305-14BAA2692C1C Q33943357-F0A9A297-9EC2-4183-A234-D7B99C4335E1 Q34036136-4D49B6C1-926B-42C3-96C8-AFE222F47A0B Q34091134-F838288A-9992-4319-A351-5E816E147A4B Q34376103-A9161625-A565-4CD2-9490-688474A821AB Q34543713-634DFE58-5F8E-4E6E-9218-0192120751EF Q34646921-911EDE4D-7787-49F9-BECF-3673B174BBBF Q35090423-2FB1ED24-35C5-40F1-986D-D01FEF95CD73 Q35169524-8D23F169-546A-4E72-AF1A-53F53F8E901B Q35658714-42F45C6E-3085-47E1-B847-EC52B60A16C4 Q35843278-F481A2EE-B5D2-4F4D-B119-299A741FB1EE Q35899066-BE83017D-BE0C-476A-986A-280F4E25304D Q36144632-F9167524-9700-4A35-80D2-C8FA7082A12D Q36300032-DA0AC3C9-C35E-459F-877C-77658ADBCB42 Q36492347-A0AF1235-488B-4CE3-93AC-B33C870A8CB9 Q36640414-D19948FE-1142-4236-BC5C-A2DD5F2FBED1 Q36729084-9B847EC0-F2DD-415E-A4BD-87B6C0B6507B Q36731881-682B1F9C-0655-4B54-9FF9-CC7781E9CC87 Q36875846-734824BD-43C1-4AB7-A2DC-B48357F7EC8E Q36876447-9B675C63-4CE1-422B-87EA-F7717A1E3A3A Q36904846-B6B43BE6-9650-4820-97B0-404A8148DF6C Q36998414-6E3095D9-A8AD-447A-BE24-D30E43F7A1CD Q37041389-99036F4C-F2E2-4E87-A786-857195581351 Q37053722-7685DD4F-C752-471F-99A2-E0E28E9C4313 Q37068847-66DAAA26-1910-407C-B9D9-D00994E837EF Q37130650-4AD18EE2-E3CE-4EEF-890F-25F31339C821 Q37154809-01FA9CCE-1BBE-4BFA-96C9-C236B7ED2DF3 Q37192883-C303DD14-1DDB-40DF-9CDD-8E6F27D389AF

P2860

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

http://www.wikidata.org/entity/Q46555308

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@en

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@nl

type

label

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@en

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@nl

prefLabel

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@en

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@nl

P1433

Q46555308-B994E699-C8DD-4C57-BF70-948B3A5CC72C

P1476

Q46555308-9A10E597-7E05-4DBD-9826-E5755776FCF6

P2093

Q46555308-1D8F16DC-19FC-48FB-8E2F-B8E04004B0BA

Q46555308-3D3AA206-9230-4DE0-A734-73D15E53C377

Q46555308-590787B8-BF9C-43CE-AEFC-0A3408E4F1D8

Q46555308-5EBD515F-1992-499C-AE6C-0A1418966958

Q46555308-93488F5E-E3A3-4C46-934F-42D658A19483

Q46555308-98E9C55C-323F-40E2-A6C0-BD5DFF8B26B3

Q46555308-ADCFA7CB-378C-4372-8778-CD5A31C80BB8

Q46555308-AE69D97E-795D-4681-9878-99118DD7B7D3

P304

Q46555308-9C7835AB-2576-4ACF-B47F-06278944150D

P31

Q46555308-8963810F-0040-4D00-B8DD-C44E9ACD66F9

P356

Q46555308-A0D1A8D5-2F39-49C7-A41C-9A8DE45A0751

P433

Q46555308-12A50638-6F25-4837-B378-AC1D66F5728D

P478

Q46555308-D41324ED-FA79-4C6C-954E-355F7B68324E

P577

Q46555308-E6784B4A-8A45-4B3D-8D3C-87E5BD685C38

P698

Q46555308-DC34EDA9-CC8A-49CA-AAED-6A34CCCA87EB

P356

01.WNF.0000167360.27670.29

P1433

Clinical Neuropharmacology

P1476

Safety, tolerability, and chan ...... etase inhibitor in volunteers.

@en

P2093

Celedon Gonzales

http://www.w3.org/2001/XMLSchema#string

Daniel Ness

http://www.w3.org/2001/XMLSchema#string

Eric Siemers

http://www.w3.org/2001/XMLSchema#string

Julie Satterwhite

http://www.w3.org/2001/XMLSchema#string

Martin Farlow

http://www.w3.org/2001/XMLSchema#string

Michael Skinner

http://www.w3.org/2001/XMLSchema#string

Patrick C May

http://www.w3.org/2001/XMLSchema#string

Robert A Dean

http://www.w3.org/2001/XMLSchema#string

P304

126-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.WNF.0000167360.27670.29

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15965311

http://www.w3.org/2001/XMLSchema#string